Michael K. Keng
Advanced in Essential Thrombocythemia

Dr. Michael K. Keng

Hematology | Oncology
University Of Virginia Physicians Group
1240 Lee St, 
Charlottesville, VA 
 (330.6 mi)
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Advanced in Essential Thrombocythemia
University Of Virginia Physicians Group
1240 Lee St, 
Charlottesville, VA 
 (330.6 mi)
OverviewInsuranceLocationsClinical Research

Overview

Michael Keng is a Hematologist and an Oncologist in Charlottesville, Virginia. Dr. Keng and is rated as an Advanced provider by MediFind in the treatment of Essential Thrombocythemia. His top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Febrile Neutropenia, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Keng is currently accepting new patients.

His clinical research consists of co-authoring 34 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Oncology
Licenses
Internal Medicine in VA
Hospital Affiliations
University Of Virginia Medical Center
Augusta Health
Languages Spoken
English
Mandarin
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Cigna
  •  UnitedHealthcare
  •  Humana
  •  Piedmont

Locations

UNIVERSITY OF VIRGINIA PHYSICIANS GROUP
1240 Lee St, Charlottesville, VA 22908

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Phase II Trial of Cardioprotective Prophylaxis with Combination of Beta Blocker and Angiotensin-Converting Enzyme Inhibitors During Intensive Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia
Phase II Trial of Cardioprotective Prophylaxis with Combination of Beta Blocker and Angiotensin-Converting Enzyme Inhibitors During Intensive Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia
Enrollment Status: Recruiting
Publish Date: February 21, 2025
Intervention Type: Drug
Study Drug: Cardioprotection
Study Phase: Phase 2
A Phase 1 Study of Ipilimumab in Combination With Decitabine in Relapsed or Refractory Myelodysplastic Syndrome/Acute Myeloid Leukemia
A Phase 1 Study of Ipilimumab in Combination With Decitabine in Relapsed or Refractory Myelodysplastic Syndrome/Acute Myeloid Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: February 21, 2025
Intervention Type: Drug, Biological
Study Drugs: Decitabine, Ipilimumab
Study Phase: Phase 1
A Randomized, Open-label, Controlled, Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults With Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy
A Randomized, Open-label, Controlled, Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults With Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: December 17, 2024
Intervention Type: Drug
Study Drugs: Pevonedistat, Venetoclax, Azacitidine
Study Phase: Phase 2
A Randomized, Double-blind, Placebo-controlled Phase III Multi-center Study of Azacitidine With or Without MBG453 for the Treatment of Patients With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)
A Randomized, Double-blind, Placebo-controlled Phase III Multi-center Study of Azacitidine With or Without MBG453 for the Treatment of Patients With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)
Enrollment Status: Completed
Publish Date: December 12, 2024
Intervention Type: Drug
Study Drugs: MBG453, Azacitidine
Study Phase: Phase 3
Phase I Study of Inotuzumab Ozogamicin With 3 and 4 Drug Augmented Berlin-Frankfurt-Münster (BFM) Re-Induction for Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL)
Phase I Study of Inotuzumab Ozogamicin With 3 and 4 Drug Augmented Berlin-Frankfurt-Münster (BFM) Re-Induction for Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL)
Enrollment Status: Active_not_recruiting
Publish Date: August 22, 2023
Intervention Type: Drug
Study Drugs: Inotuzumab ozogamicin, Prednisone, Daunorubicin, Vincristine, Cytarabine, Methotrexate, Pegaspargase
Study Phase: Phase 1
Phase 3 Multicenter Randomized Trial to Evaluate Efficacy and Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. Therapy and Control Sub-groups in Older Patients With R/R AML
Phase 3 Multicenter Randomized Trial to Evaluate Efficacy and Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. Therapy and Control Sub-groups in Older Patients With R/R AML
Enrollment Status: Terminated
Publish Date: February 08, 2023
Intervention Type: Drug
Study Drugs: CPI-613, Cytarabine, Mitoxantrone, Etoposide, Fludarabine, Filgrastim
Study Phase: Phase 3
A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent
A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent
Enrollment Status: Terminated
Publish Date: September 26, 2022
Intervention Type: Drug
Study Drug: Rigosertib
Study Phase: Phase 3
An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
Enrollment Status: Completed
Publish Date: June 16, 2022
Intervention Type: Drug
Study Drugs: Itacitinib, Ruxolitinib
Study Phase: Phase 2
A Randomized, Double-blind Phase 3 Study of Vadastuximab Talirine (SGN-CD33A) Versus Placebo in Combination With Azacitidine or Decitabine in the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
A Randomized, Double-blind Phase 3 Study of Vadastuximab Talirine (SGN-CD33A) Versus Placebo in Combination With Azacitidine or Decitabine in the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
Enrollment Status: Terminated
Publish Date: December 12, 2018
Intervention Type: Drug
Study Phase: Phase 3
View 8 Less Clinical Trials

34 Total Publications

Development and Implementation of Oral Anticancer Agent Tools for a Thematic Quality Improvement Program: A Collaboration Between Hematology Oncology Pharmacist Association and ASCO Quality Training Program.
Development and Implementation of Oral Anticancer Agent Tools for a Thematic Quality Improvement Program: A Collaboration Between Hematology Oncology Pharmacist Association and ASCO Quality Training Program.
Journal: JCO oncology practice
Published: January 23, 2025
Similar Doctors
Distinguished in Essential Thrombocythemia
Dr. Kelly M. Davidson
Hematology Oncology | Oncology | Hematology
Distinguished in Essential Thrombocythemia
Dr. Kelly M. Davidson
Hematology Oncology | Oncology | Hematology

University Of Virginia Physicians Group

1240 Lee St, 
Charlottesville, VA 
434-243-0321
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Kelly Davidson is a Hematologist Oncology specialist and an Oncologist in Charlottesville, Virginia. Dr. Davidson and is rated as a Distinguished provider by MediFind in the treatment of Essential Thrombocythemia. Her top areas of expertise are Waldenstrom Macroglobulinemia, Polycythemia Vera, Iron Deficiency Anemia, Bone Marrow Aspiration, and Splenectomy. Dr. Davidson is currently accepting new patients.

Maofu Fu
Distinguished in Essential Thrombocythemia
Dr. Maofu Fu
Hematology Oncology | Hematology | Oncology
Distinguished in Essential Thrombocythemia
Dr. Maofu Fu
Hematology Oncology | Hematology | Oncology

Rmh Medical Group LLC

2008 Health Campus Dr, 
Rockingham, VA 
 (32.2 mi)
540-689-7000
Experience:
40+ years
Languages Spoken:
English

Maofu Fu is a Hematologist Oncology specialist and a Hematologist in Rockingham, Virginia. Dr. Fu has been practicing medicine for over 40 years and is rated as a Distinguished provider by MediFind in the treatment of Essential Thrombocythemia. His top areas of expertise are Agranulocytosis, Chronic Familial Neutropenia, Febrile Neutropenia, and Childhood Iron Deficiency Anemia.

Advanced in Essential Thrombocythemia
Dr. Venkateswar R. Veerapalli
Hematology | Hematology Oncology | Oncology
Advanced in Essential Thrombocythemia
Dr. Venkateswar R. Veerapalli
Hematology | Hematology Oncology | Oncology
451 James Madison Hwy, Suite 104, 
Culpeper, VA 
 (41.6 mi)
703-635-6121
Languages Spoken:
English, Hindi, Telugu
See accepted insurances
Accepting New Patients

Venkateswar Veerapalli is a Hematologist and a Hematologist Oncology provider in Culpeper, Virginia. Dr. Veerapalli and is rated as an Advanced provider by MediFind in the treatment of Essential Thrombocythemia. His top areas of expertise are Hemochromatosis, Chronic Myelogenous Leukemia (CML), Philadelphia-Negative Chronic Myeloid Leukemia, and Childhood Iron Deficiency Anemia. Dr. Veerapalli is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile